Cortical Glutamate and GABA Changes During Early Abstinence in Alcohol Dependence and Their Associations With Benzodiazepine Medication.
1H-MR-spectroscopy
GABA
N-acetylaspartate
alcohol dependence
benzodiazepine
glutamate
withdrawal
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
01
2021
accepted:
01
06
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
In this report, we present cross-sectional and longitudinal findings from single-voxel MEGA-PRESS MRS of GABA as well as Glu, and Glu + glutamine (Glx) concentrations in the ACC of treatment-seeking alcohol-dependent patients (ADPs) during detoxification (first 2 weeks of abstinence). The focus of this study was to examine whether the amount of benzodiazepine administered to treat withdrawal symptoms was associated with longitudinal changes in Glu, Glx, and GABA. The tNAA levels served as an internal quality reference; in agreement with the vast majority of previous reports, these levels were initially decreased and normalized during the course of abstinence in ADPs. Our results on Glu and Glx support hyperglutamatergic functioning during alcohol withdrawal, by showing higher ACC Glu and Glx levels on the first day of detoxification in ADPs. Withdrawal severity is reflected in cumulative benzodiazepine requirements throughout the withdrawal period. The importance of withdrawal severity for the study of GABA and Glu changes in early abstinence is emphasized by the benzodiazepine-dependent Glu, Glx, and GABA changes observed during the course of abstinence.
Identifiants
pubmed: 34290627
doi: 10.3389/fpsyt.2021.656468
pmc: PMC8287125
doi:
Types de publication
Journal Article
Langues
eng
Pagination
656468Informations de copyright
Copyright © 2021 Wang, Weber-Fahr, Frischknecht, Hermann, Kiefer, Ende and Sack.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuropsychopharmacology. 2002 Apr;26(4):546-51
pubmed: 11927179
Alcohol Alcohol. 2012 Sep-Oct;47(5):501-8
pubmed: 22791370
Alcohol Alcohol. 1998 Nov-Dec;33(6):563-75
pubmed: 9872344
Addict Biol. 2020 Nov;25(6):e12810
pubmed: 31373138
J Magn Reson Imaging. 2016 Dec;44(6):1474-1482
pubmed: 27239903
Neuroimage. 2002 May;16(1):49-60
pubmed: 11969317
Magn Reson Med. 2001 Mar;45(3):517-20
pubmed: 11241712
Biol Psychiatry. 2012 Feb 1;71(3):239-46
pubmed: 21855054
Biol Psychiatry. 2012 Jun 1;71(11):1015-21
pubmed: 21907974
Magn Reson Med. 2013 Feb;69(2):317-20
pubmed: 22488982
Neuropharmacology. 2017 Aug 1;122:85-99
pubmed: 28108359
Mol Brain. 2017 Sep 20;10(1):45
pubmed: 28931433
Psychiatr Genet. 2018 Oct;28(5):94-95
pubmed: 29985185
Neurochem Res. 2015 Feb;40(2):402-9
pubmed: 25380696
Am J Psychiatry. 2004 Dec;161(12):2186-93
pubmed: 15569888
Drug Alcohol Depend. 2012 Sep 1;125(1-2):27-36
pubmed: 22503310
J Magn Reson Imaging. 2013 Apr;37(4):999-1003
pubmed: 23001644
Curr Top Behav Neurosci. 2013;13:511-40
pubmed: 21688208
Neuroscience. 2021 Jan 1;452:235-246
pubmed: 33246064
Alcohol Res. 2017;38(2):183-206
pubmed: 28988573
Biochem Pharmacol. 2008 Jan 1;75(1):218-65
pubmed: 17706608
NMR Biomed. 2001 Aug;14(5):325-31
pubmed: 11477653
J Clin Diagn Res. 2015 Sep;9(9):VE01-VE07
pubmed: 26500991
Alcohol Clin Exp Res. 2017 Feb;41(2):323-333
pubmed: 28098946
NMR Biomed. 1998 Oct;11(6):266-72
pubmed: 9802468
Alcohol Clin Exp Res. 2019 Feb;43(2):221-226
pubmed: 30537347
Magn Reson Med. 2018 Aug;80(2):452-461
pubmed: 29344979
Magn Reson Med. 2006 Jun;55(6):1219-26
pubmed: 16688703
Biol Psychiatry. 2005 Dec 15;58(12):974-80
pubmed: 16084857
Psychiatry Res. 2010 Dec 30;184(3):162-70
pubmed: 21036017
Psychiatry Res. 2010 Dec 30;184(3):171-6
pubmed: 21055907
Arch Gen Psychiatry. 2010 Oct;67(10):1069-77
pubmed: 20921123